Clinical Trial

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial aims to demonstrate that metformin can prevent clinical disability in patients with progressive MS by stopping or slowing down neurodegeneration by enhancing endogenous remyelination. Patients will continue their DMT treatment: metformin or placebo will be used as add-on study treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-30; most recent amendment 2025-06-18.
Status change: Recruiting → Active, Not Recruiting 2025-06-18
Status change: Not Yet Recruiting → Recruiting 2023-12-01
Trial Details
NCT Number NCT05893225
Lead Sponsor University Hospital, Antwerp
Collaborators: University Hospital, Ghent, Hasselt University, AZ Sint-Jan AV, Noorderhart Pelt, National MS Center Melsbroek
Conditions Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Enrollment 120 participants
Start Date 2023-11-23
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-24